Table 2.

Baseline cost-effectiveness analysis and probabilistic sensitivity analysis

Strategy	Costs (US$)	Incremental osts (US$)	Effectiveness (QALY)	Incremental effectiveness (QALY)	ICER ($/QALY)	ICER 95% CI ($/QALY)
SOC	155 806	–	3.16	–	–	–
SOC + caplacizumab	566 202	410 397	3.44	0.28	1 457 042	1 247 932-1 721 616

CI, confidence interval; costs, total costs of the standard of care and SOC + caplacizumab arms; effectiveness, added benefit in QALY of SOC and SOC + caplacizumab, using the assumptions described in the manuscript for utilities of the well and disease states; incremental costs, added cost of SOC + caplacizumab compared with SOC; incremental effectiveness, difference in effectiveness between SOC vs SOC + caplacizumab. The ICER is calculated by dividing incremental cost by incremental effectiveness.